Emerging agents and regimens for multiple myeloma

The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yang, Li, Yi, Gu, Huiyao, Dong, Mengmeng, Cai, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654052/
https://www.ncbi.nlm.nih.gov/pubmed/33168044
http://dx.doi.org/10.1186/s13045-020-00980-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654052/
https://www.ncbi.nlm.nih.gov/pubmed/33168044
http://dx.doi.org/10.1186/s13045-020-00980-5

Ejemplares similares